Angiogenesis as a novel component of inflammatory bowel disease pathogenesis.

BACKGROUND & AIMS Angiogenesis is a critical component of neoplastic and chronic inflammatory disorders, but whether angiogenesis also occurs in inflammatory bowel disease (IBD) has yet to be established. We assessed mucosal vascularization, expression of endothelial alphaVbeta3 integrin, angiogenic factors, and their bioactivity in Crohn's disease (CD) and ulcerative colitis (UC) mucosa. METHODS Mucosal endothelium was immunostained for CD31 and factor VIII and quantified by digital morphometry. alphaVbeta3 expression was studied in vivo by confocal microscopy and in vitro by flow cytometric analysis of human intestinal microvascular endothelial cells (HIMECs). Vascular endothelial growth factor (VEGF), interleukin (IL)-8, and bFGF levels were measured in mucosal extracts and cells and angiogenic bioactivity shown by induction of HIMEC migration and the corneal and chorioallantoic membrane angiogenesis assays. RESULTS Microvessel density was increased in IBD mucosa. Endothelial alphaVbeta3 was strongly expressed in IBD but only sporadically in normal mucosa and was up-regulated in HIMECs by VEGF, tumor necrosis factor alpha, and bFGF. IBD mucosal extracts induced a significantly higher degree of HIMEC migration than control mucosa, and this response was mostly dependent on IL-8 and less on basic fibroblast growth factor or vascular endothelial growth factor. Compared with normal mucosa, IBD mucosal extracts induced a potent angiogenic response in both the corneal and chorioallantoic membrane assays. CONCLUSIONS These results provide morphological, phenotypic and functional evidence of potent angiogenic activity in both CD and UC mucosa, indicating that the local microvasculature undergoes an intense process of inflammation-dependent angiogenesis. Thus, angiogenesis appears to be an integral component of IBD pathogenesis, providing the practical and conceptual framework for anti-angiogenic therapies in IBD.

[1]  M. Sans,et al.  Starving the inflamed gut: Angiogenesis blockade as a novel therapeutic approach to experimental colitis , 2006 .

[2]  D. Binion,et al.  The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology. , 2005, Inflammatory bowel diseases.

[3]  F. Carraro,et al.  Role of inflammatory mediators in angiogenesis. , 2005, Current drug targets. Inflammation and allergy.

[4]  X. Bian,et al.  Angiogenesis as an immunopharmacologic target in inflammation and cancer. , 2004, International immunopharmacology.

[5]  N. Ferrara,et al.  Angiogenesis-Dependent and Independent Phases of Intimal Hyperplasia , 2004, Circulation.

[6]  J. Jacobberger,et al.  Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn’s disease and ulcerative colitis , 2004, Gut.

[7]  R. Homer,et al.  Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung , 2004, Nature Medicine.

[8]  G. Corazza,et al.  Serum bFGF and VEGF Correlate Respectively with Bowel Wall Thickness and Intramural Blood Flow in Crohn’s Disease , 2004, Inflammatory bowel diseases.

[9]  J. Wilson.  Angiogenesis Therapy Moves beyond Cancer , 2004, Annals of Internal Medicine.

[10]  A. Xagorari,et al.  Angiogenesis in inflammation. , 2004, Autoimmunity reviews.

[11]  P. Tak,et al.  Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study , 2004, Arthritis research & therapy.

[12]  S. Marsal,et al.  Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. , 2004, Arthritis and rheumatism.

[13]  Sergio Romagnani,et al.  CXC chemokines: the regulatory link between inflammation and angiogenesis. , 2004, Trends in immunology.

[14]  M. Feldmann,et al.  T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. , 2004, Current drug targets. Inflammation and allergy.

[15]  C. A. de la Motte,et al.  Cutting Edge: T Cells Trigger CD40-Dependent Platelet Activation and Granular RANTES Release: A Novel Pathway for Immune Response Amplification1 , 2004, The Journal of Immunology.

[16]  S. Tyagi,et al.  Vasa vasorum in plaque angiogenesis, metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: a malignant transformation , 2004, Cardiovascular Diabetology.

[17]  A. Koch,et al.  Vascular endothelium and immune responses: implications for inflammation and angiogenesis. , 2004, Rheumatic diseases clinics of North America.

[18]  A. Gasbarrini,et al.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients , 2003, Gut.

[19]  G. Yancopoulos,et al.  Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. , 2003, Blood.

[20]  A. Dalgleish,et al.  Angiogenesis inhibitors in cancer therapy. , 2003, Current opinion in investigational drugs.

[21]  P. Carmeliet.  Angiogenesis in health and disease , 2003, Nature Medicine.

[22]  P. Choyke,et al.  Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.

[23]  C. A. de la Motte,et al.  Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. , 2003, Gastroenterology.

[24]  David Zurakowski,et al.  Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Libby,et al.  Allograft arteriosclerosis and immune-driven angiogenesis. , 2003, Circulation.

[26]  D. Ota,et al.  Angiogenic Effects of Interleukin 8 (CXCL8) in Human Intestinal Microvascular Endothelial Cells Are Mediated by CXCR2* , 2003, The Journal of Biological Chemistry.

[27]  H. Nagawa,et al.  Expression of platelet-derived endothelial cell growth factor in inflammatory bowel disease , 2003, Journal of Gastroenterology.

[28]  C. Kumar.  Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. , 2003, Current drug targets.

[29]  Wendy J. McLaren,et al.  In Vivo Detection of Morphological and Microvascular Changes of the Colon in Association with Colitis Using Fiberoptic Confocal Imaging (FOCI) , 2002, Digestive Diseases and Sciences.

[30]  V. Gould,et al.  Angiogenesis: an expanding universe. , 2002, Human pathology.

[31]  R. Wilder,et al.  Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases , 2002, Annals of the rheumatic diseases.

[32]  R. Knuechel,et al.  Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? , 2002, Histology and histopathology.

[33]  L. Ellis,et al.  The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. , 2002, Seminars in cancer biology.

[34]  R. Knuechel,et al.  Tumor-associated fibroblasts (part II): Functional impact on tumor tissue. , 2002, Histology and histopathology.

[35]  Y. Iwamoto,et al.  Fibroblast Growth Factor-2 Determines Severity of Joint Disease in Adjuvant-Induced Arthritis in Rats , 2002, The Journal of Immunology.

[36]  D. McDonald,et al.  Angiogenesis and remodeling of airway vasculature in chronic inflammation. , 2001, American journal of respiratory and critical care medicine.

[37]  G. Molema,et al.  Vascular Endothelium in Inflamed Tissue as a Target for Site Selective Delivery of Drugs , 2001 .

[38]  M. Grisham,et al.  Immunological Basis of Inflammatory Bowel Disease: Role of the Microcirculation , 2001, Microcirculation.

[39]  Takayuki Asahara,et al.  The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors , 2001, Nature Medicine.

[40]  S. Kanazawa,et al.  VEGF, basic-FGF, and TGF-β in Crohn's disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation , 2001, American Journal of Gastroenterology.

[41]  S. Kanazawa,et al.  VEGF, basic-FGF, and TGF-β in Crohn’s disease and ulcerative colitis: a novel mechanism of chronic intestinal inflammation , 2001 .

[42]  D. Walsh,et al.  Angiogenesis in the pathogenesis of inflammatory joint and lung diseases , 2001, Arthritis research.

[43]  M. Dubinsky,et al.  Doppler US in patients with crohn disease: vessel density in the diseased bowel reflects disease activity. , 2000, Radiology.

[44]  A. Koch.  The role of angiogenesis in rheumatoid arthritis: recent developments , 2000, Annals of the rheumatic diseases.

[45]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  C. Ritchlin,et al.  Fibroblast biology: Effector signals released by the synovial fibroblast in arthritis , 2000, Arthritis research.

[47]  A. Griffioen,et al.  Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. , 2000, Pharmacological reviews.

[48]  D. Cheresh,et al.  Role of alpha v integrins during angiogenesis. , 2000, Cancer journal.

[49]  M. Burdick,et al.  IL-8 is an angiogenic factor in human coronary atherectomy tissue. , 2000, Circulation.

[50]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[51]  M. Iannettoni,et al.  The CXC chemokine, monokine induced by interferon-gamma, inhibits non-small cell lung carcinoma tumor growth and metastasis. , 2000, Human gene therapy.

[52]  E. Paleolog,et al.  New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders , 1999, International journal of experimental pathology.

[53]  D. Cheresh,et al.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. , 1999, The Journal of clinical investigation.

[54]  D. Podolsky,et al.  Growth factors in inflammatory bowel disease. , 1999, Inflammatory bowel diseases.

[55]  G. Majno.  Chronic inflammation: links with angiogenesis and wound healing. , 1998, The American journal of pathology.

[56]  C. Fiocchi.  Inflammatory bowel disease: etiology and pathogenesis. , 1998, Gastroenterology.

[57]  C. Fiocchi,et al.  Proinflammatory cytokines differentially modulate their own expression in human intestinal mucosal mesenchymal cells. , 1998, Gastroenterology.

[58]  P. Carmeliet,et al.  Molecular analysis of blood vessel formation and disease. , 1997, American journal of physiology. Heart and circulatory physiology.

[59]  R. Whyte,et al.  The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. , 1997, Journal of immunology.

[60]  N. Ziats,et al.  Enhanced leukocyte binding by intestinal microvascular endothelial cells in inflammatory bowel disease. , 1997, Gastroenterology.

[61]  Ulrich Keilholz,et al.  Immunohistochemical analysis of integrin αvβ3 expression on tumor‐associated vessels of human carcinomas , 1997 .

[62]  D. Willoughby,et al.  The codependence of angiogenesis and chronic inflammation , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[64]  D. Creamer,et al.  Altered vascular endothelium integrin expression in psoriasis. , 1995, The American journal of pathology.

[65]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[66]  G. Haines,et al.  Adhesion molecule expression in human synovial tissue. , 1993, Arthritis and rheumatism.

[67]  R. Pounder,et al.  PATHOGENESIS OF CROHN'S DISEASE: MULTIFOCAL GASTROINTESTINAL INFARCTION , 1989, The Lancet.

[68]  J. Folkman.  Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.

[69]  P. Rutgeerts,et al.  Vascular endothelial growth factor (VEGF) polymorphisms are implicated in susceptibility to IBD , 2005 .

[70]  J. Willis,et al.  CD40-mediated immune-nonimmune cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. , 2004, Gastroenterology.

[71]  N. Weidner,et al.  Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors , 2004, Breast Cancer Research and Treatment.

[72]  D. Creamer,et al.  Angiogenesis in psoriasis , 2004, Angiogenesis.

[73]  Nasim Akhtar,et al.  Angiogenesis assays: a critical overview. , 2003, Clinical chemistry.

[74]  G. Molema,et al.  Development of vasculature targeting strategies for the treatment of cancer and chronic inflammatory diseases. , 2002, Biotechnology annual review.

[75]  B. Borisch,et al.  Integrin alpha(v)beta(3) expression in colon carcinoma correlates with survival. , 2001, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[76]  M. Burdick,et al.  Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint. , 2001, Arthritis and rheumatism.

[77]  W. Thompson,et al.  Angiogenesis assays using chick chorioallantoic membrane. , 2001, Methods in molecular medicine.

[78]  K J O'Byrne,et al.  The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. , 2000, European journal of cancer.

[79]  K. Pałgan.  [The role of angiogenesis in rheumatoid arthritis]. , 2000, Postępy Higieny i Medycyny Doświadczalnej.

[80]  G. Firestein,et al.  Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. , 1999, The Journal of clinical investigation.

[81]  S. Goodman,et al.  Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. , 1999, The Journal of clinical investigation.

[82]  S. Goodman,et al.  Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist , 1999 .

[83]  D. Ruiter,et al.  Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. , 1997, International journal of cancer.

[84]  D. Cheresh,et al.  Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. , 1996, Important advances in oncology.

[85]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[86]  R. Farmer,et al.  Gut mucosal lymphocytes in inflammatory bowel disease: isolation and preliminary functional characterization. , 1979, Digestive diseases and sciences.

[87]  G. Lomholt.  FOR PSORIASIS — , 1965, Maanedsskrift for praktisk laegegerning og social Medicin.